Key Highlights

● CL closed at $88.19 on 9 October 2026, and the $98.11 consensus target implies upside of about 11.2%.

● The consensus draws on 20 analysts, with targets from $87 to $110, while the second data set shows a $98.25 mean and a median of $100.

● Market data records 13 Buy and seven Hold ratings with no Sell.

● Four of the last five target changes from named brokers were reductions, including Bank of America to $100 from $102 on 9 October.

Colgate-Palmolive Company (NYSE:CL), a constituent of the S&P 500, closed at $88.19 on Friday 9 October 2026. Market data gives an average analyst price target of $98.11, about 11.2% above that close, and the second data set shows a near-identical mean of $98.25.

What Is the Latest Analyst Price Target?

Market data reports a consensus 12-month target of $98.11 from 20 analysts with ratings in the past 12 months. The highest target is $110 and the lowest is $87. The second data set, with data dated 9 October 2026, shows a mean of $98.25, a median of $100, a high of $110 and a low of $87 from 21 analysts. The two data sets are very close, although they differ slightly on the analyst count and on the closing price, which the second data set shows as $88.27. The averages are in line with recent named broker targets, which range from $87 to $110.

What Are Wall Street Analysts Saying?

The tone is moderately positive but has softened. Market data records 13 Buy ratings, seven Hold ratings and no Sell ratings. The second data set shows 13 Buy or Strong Buy ratings, eight Holds and no Sells.

Recent named broker actions show a number of reductions. Bank of America lowered its target from $102 to $100 on 9 October and kept a Buy rating. Wells Fargo cut its target from $95 to $90 on 5 October with an Equal Weight rating. BNP Paribas Exane reduced its target from $101 to $97 on 28 September with an Outperform rating, and Piper Sandler lowered its target from $98 to $95 on 21 September with an Overweight rating.

Evercore bucked the trend by raising its target from $100 to $101 on 8 October with an Outperform rating. RBC reiterated an Outperform rating with a $104 target on 8 September. In early August, UBS raised its target from $106 to $109, Morgan Stanley moved from $100 to $104, and TD Cowen raised from $85 to $90 with a Hold rating. Citigroup raised its target from $105 to $110 on 14 July. Market data also notes that an independent ratings service downgraded the stock from Buy to Hold on 2 October.

What Could Help the Stock Reach the Price Target?

Market data reports earnings per share of $0.99 for the latest quarter against a consensus estimate of $0.947. If the company continues to beat expectations, analysts who have recently trimmed targets may reconsider. The stock also pays a quarterly dividend of $0.53, equal to a yield of about 2.4% on market data's figures, which some investors regard as a source of stability for a consumer staples business.

What Could Prevent the Stock Reaching the Target?

Four of the last five target changes from named brokers were reductions, which suggests that analysts have become somewhat more cautious.

Colgate-Palmolive's Aligned Averages Meet a Run of Small Trims

Colgate-Palmolive closed at $88.19 on 9 October 2026, with the $98.11 consensus target about 11.2% higher and in line with named broker targets that range from $87 to $110. The tone is moderately positive but has softened: four of the last five named target changes were reductions, and Evercore's $101 raise stands against trims from Bank of America, Wells Fargo, BNP Paribas Exane and Piper Sandler. Market data shows earnings per share of $0.99 against $0.947 and a quarterly dividend of $0.53, a yield of about 2.4%.